Available exclusively through SCMP Research

China Healthcare Report 2020

China Healthcare Report 2020
China Healthcare Report 2020
China Healthcare Report 2020
China Healthcare Report 2020
China Healthcare Report 2020
China Healthcare Report 2020
China Healthcare Report 2020

A thorough review of the world’s second largest healthcare market
Latest examples in innovation and cost containment in the industry
Insights on Covid-19 induced market shifts
Implications to global businesses and investors

USD $400
Request for a copy of the sample pages

87-page report with data, analyses, and market insights

6 closed-door webinars led by China healthcare’s most influential C-suite executives

+ live Q&A sessions with executives and SCMP reporters

Exclusive case studies covering 5 segments in healthcare

WHAT'S INSIDE

Report Overview

  • Market Overview
    Background, Market Size, Main segments, Major diseases, Funding, Government Policies
  • Segment Trends
    Pharmaceuticals, Biopharmaceuticals & Contract Service, Medical Devices and Supplies, Healthcare Service Providers, Healthcare Technology
  • Risks and Opportunities
    Transparency in Focus, Quality Concerns, Geopolitical Challenges, Overcrowding and Exuberance, A New Model

5 Deep-dive Segments

Features data & analyses, market insights, and case studies

Service icon

Pharmaceuticals

  • Landscape of leading global and local pharmaceuticals
  • Drug distribution reform and the “two-invoices system”
  • Growth in R&D spending
  • Emerging API exports
  • Case study on 111, Inc.





Service icon

Biopharmaceuticals and Contract Services

  • Fast-tracking drug approvals
  • A surge of in-license deals
  • In the pipeline: biosimilars and “first-in-class” candidates
  • Chinese biopharma’s overseas expansion and partnerships
  • Contracted services: CRO and CDMO
  • Case studies on Chi-Med, Hua Medicine, and Zai Lab
Service icon

Biopharmaceuticals and Contract Services

  • Fast-tracking drug approvals
  • A surge of in-license deals
  • In the pipeline: biosimilars and “first-in-class” candidates
  • Chinese biopharma’s overseas expansion and partnerships
  • Contracted services: CRO and CDMO
  • Case studies on Chi-Med, Hua Medicine, and Zai Lab
Service icon

Biopharmaceuticals and Contract Services

  • Fast-tracking drug approvals
  • A surge of in-license deals
  • In the pipeline: biosimilars and “first-in-class” candidates
  • Chinese biopharma’s overseas expansion and partnerships
  • Contracted services: CRO and CDMO
  • Case studies on Chi-Med, Hua Medicine, and Zai Lab
Service icon

Biopharmaceuticals and Contract Services

  • Fast-tracking drug approvals
  • A surge of in-license deals
  • In the pipeline: biosimilars and “first-in-class” candidates
  • Chinese biopharma’s overseas expansion and partnerships
  • Contracted services: CRO and CDMO
  • Case studies on Chi-Med, Hua Medicine, and Zai Lab
Service icon

Medical Devices and Supplies

  • Market segmentation: imports vs. local products
  • “Made in China 2025”: focus on high-end devices 
  • Financial windfall from Covid-19
  • Case study on Venus Medtech
Service icon

Healthcare Service Providers

  • An “inverted pyramid” - China’s healthcare system
  • Healthcare reform to strengthen the primary care infrastructure
  • Private hospitals on the rise
  • The role of private insurance
  • Case study on United Family Healthcare
Service icon

Healthcare Technology

  • From genome sequencing to the vaccine search
  • Accelerated adoption of AI during Covid-19
  • Remote healthcare through telemedicine platforms
  • Case study on Baidu Healthcare

ALSO INCLUDED

6 Closed-door Webinars with C-level Executives

Includes live Q&A sessions with executives and SCMP reporters

Dr. Li Chen

CEO of
Hua Medicine

Pharmaceutical
Topic Coming Soon!

COMING SOON

Elaine Chu

General Manager of
Quality Healthcare Medical Services

Healthcare Service Provider
Topic Coming Soon!

Coming Soon

Dr. Samantha Du

CEO of
Zai Lab

Biopharmaceutical
Topic Coming Soon!

Coming Soon

Christian Hogg

CEO of
Chi-Med

China Biopharma Boom:
Accelerating Global Expansion

SCHEduled On Sep 29, 2020

Li Ma

Senior Vice President of
Alibaba Health

Healthtech in China:
From healthcare e-commerce to AI

SCHEDULED ON OCT 13, 2020

Dr. Gang Yu

Co-founder and
Executive Chairman of 111, Inc.

Online pharmacy and telemedicine:
Will China lead the world in adoption?

Watch the replay here

A most comprehensive and high-quality research report covering very relevant subjects and citing excellent case studies and examples. A most valuable document for industry entrepreneurs, investors and policy makers!

Dr. Donald Li Kwok-Tung

President, World Organization of Family Doctors

The report gives a full account of historical context, current landscape, and emerging trends of China’s healthcare sector. The recent rise in online care and AI-empowered developments amid the COVID-19 outbreak is also well depicted.

Dr. Gang Yu

Co-founder and Executive Chairman, 111, Inc.

PRICING PLANS

Choose the plan that suits you best

Individual Plan

  • China Healthcare Report 2020
  • 6 webinar sessions with healthcare experts

US$400

Enterprise Plan

  • China Healthcare Report 2020
    (Multiple copies / IP access)
  • 6 webinar sessions with healthcare experts
    (Multiple logins)


CONTACT US

Contact Us

For business enquiries, customer feedback and questions, email us at research@scmp.com

The content of this report is for information purposes only. Whilst every effort has been made to ensure accuracy, no warranty, expressed or implied is given on merchantability, accuracy, reliability and correctness of the content. We expressly exclude any and all liability, to the extent permissible under law, including but not limited to tort, negligence, all losses, damages, costs suffered or incurred by anyone in reliance on the report. You are specifically drawn to the attention that the report is not meant to be relied on and should not be construed as advice of any kind or the basis for making any commercial decision including but not limited to any investment decisions. The report may consist of opinion, data and information obtained from a wide range of sources, both public and private, market research, interviews and third party resources. We cite specific sources where data, research or insights are obtained from any third party. Any trademarks or service marks used in this report are the marks of their respective owners and may not have contributed to the content of the report and should not be read or construed as having made any endorsement to the content of the same. All rights in such marks are reserved by their respective owners. Purchase is nonrefundable and is subject to terms and conditions. Please visit here for details.